Abstract:Prion diseases are caused by the conversion of normal cellular prion proteins (PrP) into lethal prion aggregates. These prion aggregates are composed of proteinase K (PK) resistant fibrils and comparatively PK-sensitive oligomers. Currently there are no anti-prion pharmaceuticals available to treat or prevent prion disease. Methods of discovering anti-prion molecules rely primarily on relatively complex cell-based, tissue slice or animal-model assays that measure the effects of small molecules on the formation of PK-resistant prion fibrils. These assays are difficult to perform and do not detect the compounds that directly inhibit oligomer formation or alter prion conversion kinetics. We have developed a simple cell-free method to characterize the impact of anti-prion fibril compounds on both the oligomer and fibril formation. In particular, this assay uses shaking-induced conversion (ShIC) of recombinant PrP in a 96-well format and resolution enhanced native acidic gel electrophoresis (RENAGE) to generate, assess and detect PrP fibrils in a high throughput fashion. The end-point PrP fibrils from this assay can be further characterized by PK analysis and negative stain transmission electron microscopy (TEM). This cell-free, gel-based assay generates metrics to assess anti-prion fibril efficacy and kinetics. To demonstrate its utility, we characterized the action of seven well-known anti-prion molecules: Congo red, curcumin, GN8, quinacrine, chloropromazine, tetracycline, and TUDCA (taurourspdeoxycholic acid), as well as four suspected anti-prion compounds: trans-resveratrol, rosmarinic acid, myricetin and ferulic acid. These findings suggest that this in vitro assay could be useful in identifying and comprehensively assessing novel anti-prion fibril compounds. Abbreviations: PrP, prion protein; PK, proteinase K; ShIC, shaking-induced conversion; RENAGE, resolution enhanced native acidic gel electrophoresis; TEM, transmission electron microscopy; TUDCA, taurourspdeoxycholic acid; BSE, bovine spongiform encephalopathy; CWD, chronic wasting disease; CJD, Creutzfeldt Jakob disease; GSS, Gerstmann-Sträussler-Scheinker syndrome; FFI, fatal familial insomnia; PrPc, cellular prion protein; recPrPC, recombinant monomeric prion protein; PrPSc, infectious particle of misfolded prion protein; RT-QuIC, real-time quaking-induced conversion; PMCA, Protein Misfolding Cyclic Amplification; LPS, lipopolysaccharide; EGCG, epigallocatechin gallate; GN8, 2-pyrrolidin-1-yl-N-[4-[4-(2-pyrrolidin-1-yl-acetylamino)-benzyl]-phenyl]-acetamide; DMSO, dimethyl sulfoxide; ScN2A, scrapie infected neuroblastoma cells; IC50, inhibitory concentration for 50% reduction; recMoPrP 23-231, recombinant full-length mouse prion protein residues 23-231; EDTA; PICUP, photo-induced cross-linking of unmodified protein; BSA, bovine serum albumin;; PMSF, phenylmethanesulfonyl fluoride.

Capillary Isoelectric Focusing and Affinity Capillary Electrophoresis Approaches for the Determination of Binding Constants for Antibodies to the Prion Protein

Preparations of Specific Antibodies Against PrP N-terminal or C-terminal Peptides and Preliminary Study on Establishment of ELISA Diagnostic Method

Detection of Prion Protein Using a Capillary Electrophoresis-Based Competitive Immunoassay with Laser-Induced Fluorescence Detection and Cyclodextrin-Aided Separation

Capillary Electrophoresis-Based Noncompetitive Immunoassay for the Prion Protein Using Fluorescein-Labeled Protein A As a Fluorescent Probe

PrP(Sc)-specific Antibodies with the Ability to Immunodetect Prion Oligomers.

Improved conformation-dependent immunoassay: suitability for human prion detection with enhanced sensitivity

A simple in vitro assay for assessing the efficacy, mechanisms and kinetics of anti-prion fibril compounds

PrP Protein Can Bind to Protein Kinase CK2 Both in Native and Recombinant Forms in Vitro

Human Anti-prion Antibodies Block Prion Peptide Fibril Formation and Neurotoxicity

Immunological Characteristics of Anti-PrP McAbs

Simple Method of Monoclonal Antibody Production Against Mammalian Cellular Prion Protein

A Label-Free and Cascaded Dual-Signaling Amplified Electrochemical Aptasensing Platform for Sensitive Prion Assay.

Guanidine hydrochloride extraction and detection of prion proteins in mouse and hamster prion diseases by ELISA

An Enzyme-Linked Immunosorbent Assay To Compare The Affinity Of Chemical Compounds For Beta-Amyloid Peptide As A Monomer

Noncompetitive Immunoassays Using Protein G Affinity Capillary Chromatography and Capillary Electrophoresis with Laser-Induced Fluorescence Detection.

A New Electrochemical Immunosensor for Sensitive Detection of Prion Based on Prussian Blue Analogue.

Synthesizing and Immunization Analysis of Bovine PrPc Structural Protein Peptides

[Determination of the Binding Constants of Four Anti-Hiv-1 Active Compounds with Bovine Serum Albumin by Capillary Zone Electrophoresis].

Development of an indirect ELISA for determination of antigen-binding activity of monoclonal antibody against proprotein convertase subtilisin/kexin type 9

Detection of Abnormal Prion Protein by Immunohistochemistry

Evaluation Of The Effect Of Various Main Elements On The Prpsc Detection By Real-Time Quaking-Induced Conversion Assay